Urothelial carcinoma
Conditions
Interventions
Test group:Terarelizumab
Sponsors
Beijing Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients with urothelial carcinoma ( including bladder cancer, ureteral cancer and renal pelvic cancer ) ; patients without distant metastasis within 3 months after radical resection ; preoperative neoadjuvant patients were ypT2-4a or ypN +. Preoperative non-neoadjuvant : pT3-T4a or pTX N +
Exclusion criteria
Exclusion criteria: suffering from severe bleeding tendency or blood coagulation disease; patients with severe heart, brain, lung, liver, kidney and other visceral diseases or nervous system lesions; the researchers believe that other reasons are not suitable for clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1 year disease-free recurrence rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| 1-year completion rate of immunotherapy;incidence of adverse reactions;no disease recurrence rate in patients with bladder cancer and upper urothelial carcinoma for 1 year; | — |
Countries
China
Contacts
Public ContactZhang Yaqun
NO.1 DaHua Road, Dong Dan, Beijing
Outcome results
None listed